7.20Open7.20Pre Close0 Volume10 Open Interest7.50Strike Price0.00Turnover270.80%IV-16.76%PremiumJan 17, 2025Expiry Date10.16Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9887Delta0.0041Gamma1.73Leverage Ratio-0.0123Theta0.0017Rho1.71Eff Leverage0.0008Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet